Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics. (December 2016) - André, F.; Stemmer, S.M.; Hortobagyi, G.N.; Burris, H.A.; Paluch-Shimon, S.; Campone, M.; Villanueva, C.; Chan, A.; Wist, E.; Marschner, N.; Bachelot, T.; Blau, S.; et al.